Philippine News Agency
PH approves emergency use of Novavax Covid-19 vaccine
The Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for Novavax's COVID-19 vaccine, Covovax.
Covovax is a protein subunit vaccine, meaning it replicates a pure portion of the virus's antigenic part to elicit an immune response.
The vaccine is approved for individuals aged 18 and above and is administered in two doses with a three to four-week interval.
Clinical trials showed Covovax has a very mild adverse event profile and an efficacy rate of approximately 89.7% in preventing COVID-19.
🤖
This story was generated by AI to help you understand the key points. For more detailed coverage, please see the news articles from trusted media outlets below.
News Sources
See how different news organizations are covering this story. Below are the original articles from various Philippine news sources that contributed to this summary.
The Philippines has granted emergency use authorization (EUA) for Novavax's COVID-19 vaccine, Covovax, for individuals aged 18 and above.
Read more →
The Philippine Food and Drug Administration (FDA) is aiming to grant full marketing authorization for several COVID-19 vaccines by the first quarter of 2022.
Read more →
The Food and Drug Administration (FDA) has authorized four COVID-19 vaccine brands – Pfizer-BioNTech, AstraZeneca, and Sinovac – to be used as homologous (same brand) additional doses.
Read more →